港股異動 | 中國三江化工(2198.HK)高開4.85% 中期純利同比增長1057.7%
格隆匯8月28日丨中國三江化工(2198.HK)高開4.85%,報2.16港元,最新總市值25億港元。公司昨日晚間公佈中期業績稱,期內實現收益37.78億元(人民幣,下同),同比減少9.8%;股東應占純利3.74億元,同比增加1057.7%;基本每股盈利31.61分,擬派每股中期股息12.5港仙。期內收益減少主要由於:1)與2019年同期相比,集團主要產品(即環氧乙烷、乙二醇及聚丙烯)於2020年上半年的平均售價下跌約10.8%至約18.4%;及2)集團的第五期環氧乙烷╱乙二醇生產設施於2020年上半年維持滿負荷營運,並通過產能轉換全力生產環氧乙烷。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.